MedPath

Furosemide

Generic Name
Furosemide
Brand Names
Furoscix, Lasix
Drug Type
Small Molecule
Chemical Formula
C12H11ClN2O5S
CAS Number
54-31-9
Unique Ingredient Identifier
7LXU5N7ZO5
Background

Furosemide is a potent loop diuretic that acts on the kidneys to ultimately increase water loss from the body. It is an anthranilic acid derivative. Furosemide is used for edema secondary to various clinical conditions, such as congestive heart failure exacerbation, liver failure, renal failure, and high blood pressure. It mainly works by inhibiting electrolyte reabsorption from the kidneys and enhancing the excretion of water from the body. Furosemide has a fast onset and short duration of action and has been used safely and effectively in both pediatric and adult patients. The use of furosemide is particularly beneficial in clinical settings that require a drug with a higher diuretic potential. In addition to oral formulations, the solution for intravenous and intramuscular administration is also available, which is typically limited to patients who are unable to take oral medication or for patients in emergency clinical situations.

Indication

Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.

Oral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications.

Intravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desired.

Subcutaneous furosemide is indicated for the treatment of congestion due to fluid overload in adults with NYHA Class II/III chronic heart failure. This drug formulation is not indicated for emergency situations or in patients with acute pulmonary edema.

Associated Conditions
Acute Pulmonary Edema, Ascites, Body Fluid Retention, Edema, Hypertension, Mild to Moderate Hypertension, Chest congestion
Associated Therapies
-

Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure

Not Applicable
Conditions
Heart Failure
Interventions
First Posted Date
2009-06-18
Last Posted Date
2009-06-18
Lead Sponsor
Hennepin County Medical Center, Minneapolis
Target Recruit Count
8
Registration Number
NCT00924014
Locations
🇺🇸

Hennepin county Medical Center, Minneapolis, Minnesota, United States

Effect of Repeated Dosing of Naproxcinod on Renal Hemodynamic and on Sodium Balance in Healthy Volunteers Before and After a Single Dose of Furosemide

Phase 1
Completed
Conditions
Renal Hemodynamics
Interventions
First Posted Date
2009-05-28
Last Posted Date
2011-06-17
Lead Sponsor
NicOx
Target Recruit Count
31
Registration Number
NCT00909519

Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure

Phase 4
Terminated
Conditions
Acute Decompensated Heart Failure
Interventions
Drug: Addition of oral Metolazone
Drug: Furosemide dose escalation
First Posted Date
2009-05-19
Last Posted Date
2018-03-13
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
11
Registration Number
NCT00904488
Locations
🇺🇸

UNC_Chapel Hill, Chapel Hill, North Carolina, United States

Protocol to Assess the Severity of Acute Kidney Injury

Not Applicable
Completed
Conditions
Acute Kidney Failure
Interventions
First Posted Date
2008-05-07
Last Posted Date
2022-10-18
Lead Sponsor
George Washington University
Target Recruit Count
77
Registration Number
NCT00673244
Locations
🇺🇸

George Washington University Hospital, Washington, District of Columbia, United States

A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
First Posted Date
2008-05-05
Last Posted Date
2012-03-19
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
48
Registration Number
NCT00671424
Locations
🇺🇸

GSK Investigational Site, Columbus, Ohio, United States

Using Furosemide to Prevent Fluid Overload During Red Blood Cell Transfusion in Neonates

Phase 3
Conditions
Lung Disease
Interventions
Drug: Saline
Drug: Furosemide
First Posted Date
2008-02-20
Last Posted Date
2008-02-20
Lead Sponsor
The Hospital for Sick Children
Target Recruit Count
64
Registration Number
NCT00618852
Locations
🇨🇦

The Hospital for Sick Children, Toronto, Ontario, Canada

🇨🇦

Mount Sinai Hospital, Toronto, Ontario, Canada

Nephropathy In Type 2 Diabetes and Cardio-renal Events

First Posted Date
2007-09-27
Last Posted Date
2020-08-03
Lead Sponsor
University of Campania "Luigi Vanvitelli"
Target Recruit Count
850
Registration Number
NCT00535925
Locations
🇮🇹

Department of Advanced Medical and Surgical Sciences, Università della Campania "Luigi Vanvitelli", Naples, Italy, Naples, Italy

Physiopathology of Sodium Retention in Acromegaly

Not Applicable
Completed
Conditions
Acromegaly
Interventions
First Posted Date
2007-09-19
Last Posted Date
2011-12-07
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
12
Registration Number
NCT00531908
Locations
🇫🇷

Hopital Bicetre, Paris, France

Furosemide Inhalation in Dyspnea of Mustard Gas Exposed Patients

Phase 3
Completed
Conditions
Bronchiolitis
First Posted Date
2007-08-08
Last Posted Date
2007-08-08
Lead Sponsor
Baqiyatallah Medical Sciences University
Registration Number
NCT00512811
Locations
🇮🇷

RCCI, Tehran, Iran, Islamic Republic of

Loop Diuretics in Chronic Kidney Disease

Phase 4
Completed
Conditions
Chronic Kidney Disease
Interventions
First Posted Date
2007-05-25
Last Posted Date
2009-02-04
Lead Sponsor
University of Campania "Luigi Vanvitelli"
Target Recruit Count
40
Registration Number
NCT00478543
Locations
🇮🇹

Nephrology Department, Second University of Naples, Naples, Italy

© Copyright 2025. All Rights Reserved by MedPath